- Home
- SLN
as 07-01-2025 3:42pm EST
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
| Founded: | 1994 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 281.0M | IPO Year: | N/A |
| Target Price: | $32.60 | AVG Volume (30 days): | 111.7K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.97 - $22.46 | Next Earning Date: | 08-14-2025 |
| Revenue: | $27,701,000 | Revenue Growth: | -16.00% |
| Revenue Growth (this year): | -25.23% | Revenue Growth (next year): | N/A |
Latest Silence Therapeutics Plc American Depository Share News
SLN Breaking Stock News: Dive into SLN Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Up 2.5% for Week
MT Newswires
7 days ago
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
MT Newswires
14 days ago
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
MT Newswires
19 days ago
Silence Therapeutics Says Diversiran Profile Remains 'Compelling' in Updated Data
Business Wire
19 days ago
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera
Simply Wall St.
20 days ago
One Silence Therapeutics Insider Raised Stake By 15% In Previous Year
Zacks
25 days ago
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
Zacks
a month ago
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade
Compare SLN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLN Silence Therapeutics Plc American Depository Share - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.